中国胃肠间质瘤酪氨酸激酶抑制剂相关不良反应管理专家共识。
Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors.
机构信息
Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing 100142, China.
Department of Gastrointestinal Surgery, Reiji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200127, China.
出版信息
World J Gastroenterol. 2018 Dec 14;24(46):5189-5202. doi: 10.3748/wjg.v24.i46.5189.
Tyrosine kinase inhibitors (TKIs) have improved the overall survival of patients with gastrointestinal stromal tumors (GISTs), but their side effects can impact dose intensity and, consequently, the clinical benefit. To date, no guideline or consensus has been published on the TKI-associated adverse reactions. Therefore, the Chinese Society of Surgeons for Gastrointestinal Stromal Tumor of the Chinese Medical Doctor Association organized an expert panel discussion involving representatives from gastrointestinal surgery, medical oncology, cardiology, dermatology, nephrology, endocrinology, and ophthalmology to consider the systemic clinical symptoms, molecular and cellular mechanisms, and treatment recommendations of GISTs. Here, we present the resultant evidence- and experience-based consensus to guide the management of TKI-associated side events in clinical practice.
酪氨酸激酶抑制剂（TKIs）改善了胃肠道间质瘤（GIST）患者的总生存率，但它们的副作用会影响剂量强度，从而影响临床获益。迄今为止，尚未发表关于 TKI 相关不良反应的指南或共识。因此，中国医师协会外科医师分会胃肠道间质瘤专委会组织了一次专家小组讨论，邀请了来自胃肠外科、肿瘤内科、心血管内科、皮肤科、肾内科、内分泌科和眼科的代表，共同探讨 GIST 的全身临床症状、分子和细胞机制以及治疗建议。在此，我们根据现有的证据和经验制定了共识，以指导临床实践中 TKI 相关不良反应的管理。
Zotero 插件